Search Within

Anita Kumar

Formats
  1. Meeting Abstract (98)
  2. Journal Article (63)
  3. Review (7)
  4. Book Section (6)
  5. Research Letter (4)
  6. Correspondence (1)
  7. Editorial (1)
Groups
  1. Center for Hematologic Malignancies (180)
  2. Department of Medicine (180)
  3. Hematologic Malignancies, Division of (180)
  4. Lymphoma (180)
  5. Survivorship Research (100)
  6. Population Sciences Research Program (91)

More Groups

People
  1. Andrew Zelenetz (123)
  2. Paul Hamlin (94)
  3. Alison Moskowitz (93)
  4. Ariela Noy (93)
  5. Maria Palomba (87)
  6. Steven Horwitz (87)

More People

Years
  1. 2025 (4)
  2. 2024 (19)
  3. 2023 (32)
  4. 2022 (12)
  5. 2021 (24)
  6. 2020 (17)

More Years

Publications
  1. Blood (70)
  2. Hematological Oncology (19)
  3. Journal of Clinical Oncology (12)
  4. Blood Advances (11)
  5. Haematologica (9)
  6. Leukemia and Lymphoma (7)

More Publications

Publishers
  1. American Society of Hematology (82)
  2. Wiley Blackwell (19)
  3. American Society of Clinical Oncology (12)
  4. Nature Publishing Group (10)
  5. Ferrata Storti Foundation (9)
  6. Taylor & Francis Group (8)

More Publishers

Results (180)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes of patients with positive interim positron emission tomography (PET) continuing ABVD in the clinical setting
    Journal Article

    Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S.; Kumar, A.; Matasar, M. J.; more...
    Cancers (2023)

    Fulltext@MSK | Save
  • Personalized approaches for treatment-naïve mantle cell lymphoma
    Review

    Qualls, D.; Kumar, A.
    Expert Review of Hematology (2023)

    Fulltext@MSK | Save
  • Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era
    Research Letter

    Qualls, D.; Imber, B. S.; Okwali, M.; Hamlin, P. A.; Kumar, A.; Lahoud, O. B.; Matasar, M. J.; Noy, A.; Owens, C.; Zelenetz, A. D.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: Results from large real-world cohorts
    Journal Article

    Martin, P.; Cohen, J. B.; Wang, M.; Kumar, A.; Hill, B.; Villa, D.; Switchenko, J. M.; Kahl, B.; Maddocks, K.; Grover, N. S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed / refractory mantle cell lymphoma: Additional patients and extended follow-up from the phase 1/2 BRUIN study
    Meeting Abstract

    Wang, M. L.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C. Y.; Ujjani, C. S.; Koh, Y.; Izutsu, K.; Gerson, J. N.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2
    Meeting Abstract

    Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: A phase II risk-adapted design
    Journal Article

    Kumar, A.; Casulo, C.; Joffe, E.; Moskowitz, C.; Gerecitano, J.; Moskowitz, A.; Younes, A.; Drullinsky, P.; Drill, E.; Choma, M.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save